全文获取类型
收费全文 | 91095篇 |
免费 | 5261篇 |
国内免费 | 214篇 |
专业分类
耳鼻咽喉 | 1083篇 |
儿科学 | 2087篇 |
妇产科学 | 2039篇 |
基础医学 | 12375篇 |
口腔科学 | 3453篇 |
临床医学 | 7179篇 |
内科学 | 22052篇 |
皮肤病学 | 2138篇 |
神经病学 | 8141篇 |
特种医学 | 2152篇 |
外国民族医学 | 1篇 |
外科学 | 12235篇 |
综合类 | 431篇 |
一般理论 | 39篇 |
预防医学 | 7840篇 |
眼科学 | 1839篇 |
药学 | 6072篇 |
中国医学 | 327篇 |
肿瘤学 | 5087篇 |
出版年
2023年 | 560篇 |
2022年 | 456篇 |
2021年 | 1643篇 |
2020年 | 976篇 |
2019年 | 1693篇 |
2018年 | 2835篇 |
2017年 | 1831篇 |
2016年 | 1932篇 |
2015年 | 2552篇 |
2014年 | 2757篇 |
2013年 | 3781篇 |
2012年 | 7734篇 |
2011年 | 8023篇 |
2010年 | 3692篇 |
2009年 | 2748篇 |
2008年 | 6648篇 |
2007年 | 6889篇 |
2006年 | 6753篇 |
2005年 | 6484篇 |
2004年 | 5839篇 |
2003年 | 5332篇 |
2002年 | 5017篇 |
2001年 | 1851篇 |
2000年 | 2359篇 |
1999年 | 1271篇 |
1998年 | 339篇 |
1997年 | 283篇 |
1996年 | 271篇 |
1995年 | 238篇 |
1994年 | 195篇 |
1993年 | 180篇 |
1992年 | 278篇 |
1991年 | 268篇 |
1990年 | 197篇 |
1989年 | 206篇 |
1988年 | 193篇 |
1987年 | 153篇 |
1986年 | 177篇 |
1985年 | 162篇 |
1984年 | 179篇 |
1983年 | 120篇 |
1982年 | 132篇 |
1981年 | 119篇 |
1980年 | 116篇 |
1979年 | 88篇 |
1978年 | 72篇 |
1977年 | 70篇 |
1976年 | 76篇 |
1974年 | 90篇 |
1973年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
991.
María Velasco Latrás Luis Carreras Coderch Fernando Antoñanzas Villar Juan Coya Viña José Martín Comín Francisco Martínez Carderón José Nieto Martín-Bejarano Alberto Sáenz Cusí Gala Serrano Bermúdez Amaya Echevarría Icaza 《Clinical & translational oncology》2005,7(5):198-204
Objective. To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet®) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases. Method. A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts. Results. The cost of pain control per patient is ? 12,515.39 for conventional therapy and ? 5,595.52 for samarium-153 (Quadramet®) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet®) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust. Conclusion. Samarium-153 (Quadramet®) is costeffective in treating pain in patients with prostate cancer and bone metastases. 相似文献
992.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. 总被引:11,自引:0,他引:11
Andre Goy Anas Younes Peter McLaughlin Barbara Pro Jorge E Romaguera Frederick Hagemeister Luis Fayad Nam H Dang Felipe Samaniego Michael Wang Kristine Broglio Barry Samuels Frederic Gilles Andreas H Sarris Susan Hart Elizabeth Trehu David Schenkein Fernando Cabanillas Alma M Rodriguez 《Journal of clinical oncology》2005,23(4):667-675
PURPOSE: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles. RESULTS: Sixty patients with a median number of prior therapies of 3.5 (range, one to 12 therapies) were enrolled; 33 patients were in arm A and 27 were in arm B, including 12 diffuse large B-cell lymphomas, five follicular lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma. In arm A, 12 of 29 assessable patients responded (six complete responses [CR] and six partial responses [PR]) for an overall response rate (ORR) of 41% (95% CI, 24% to 61%), and a median time to progression not reached yet, with a median follow-up of 9.3 months (range, 1.7 to 24 months). In arm B, four of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirmed, one diffuse large B-cell lymphoma patient had a PR, and one WM patient had a PR) for an ORR of 19% (95% CI, 5% to 42%). Grade 3 toxicity included thrombocytopenia (47%), gastrointestinal (20%), fatigue (13%), neutropenia (10%), and peripheral neuropathy (5%). Grade 4 toxicity occurred in nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdrawal from study. CONCLUSION: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents. 相似文献
993.
The diagnostic usefulness of sentinel lymph node biopsy (SLNB) has been well established, but its therapeutic value remains
unproven. First introduced by Morton and colleagues, the SLNB procedure is now widely available, and markedly enhances our
ability to pathologically stage the regional nodes.
Although the SLN status is acknowledged as the most powerful indicator of prognosis in melanoma, there is no evidence to-date,
of survival advantage for complete lymphadenectomy in SLN-positive patients. Also, there is no effective adjuvant therapy
that could benefit these sentinel node-positive patients, as yet. Additionally, new data have emerged indicating a possible
increase in local/in-transit recurrence following complete lymphadenectomy in sentinel node-positive patients. To understand
fully and to evaluate these observations we need information from randomized controlled trials.
Major changes have occurred following the latest revision of melanoma staging system (AJCC, 6th edition). Concerning N category,
these include the incorporation of the number of metastatic lymph nodes, the tumour burden of nodal metastases, and the ulceration
of the primary tumour. The data obtained from the new staging system will reflect differences in prognosis that were not previously
emphasized and which, we hope, will serve as a guide to more accurate analysis of metastatic pathways in cutaneous melanoma
as well as a rationale for new forms of treatment. 相似文献
994.
995.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 总被引:15,自引:0,他引:15
Daphne W Bell Thomas J Lynch Sara M Haserlat Patricia L Harris Ross A Okimoto Brian W Brannigan Dennis C Sgroi Beth Muir Markus J Riemenschneider Renee Bailey Iacona Annetta D Krebs David H Johnson Giuseppe Giaccone Roy S Herbst Christian Manegold Masahiro Fukuoka Mark G Kris José Baselga Judith S Ochs Daniel A Haber 《Journal of clinical oncology》2005,23(31):8081-8092
PURPOSE: Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but the predictive value of these mutations has not been defined in large clinical trials. The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib. PATIENTS AND METHODS: We analyzed the frequency of EGFR mutations in lung cancer specimens from both the IDEAL and INTACT trials and compared it with EGFR gene amplification, another genetic abnormality in NSCLC. RESULTS: EGFR mutations correlated with previously identified clinical features of gefitinib response, including adenocarcinoma histology, absence of smoking history, female sex, and Asian ethnicity. No such association was seen in patients whose tumors had EGFR amplification, suggesting that these molecular markers identify different biologic subsets of NSCLC. In the IDEAL trials, responses to gefitinib were seen in six of 13 tumors (46%) with an EGFR mutation, two of seven tumors (29%) with amplification, and five of 56 tumors (9%) with neither mutation nor amplification (P = .001 for either EGFR mutation or amplification v neither abnormality). Analysis of the INTACT trials did not show a statistically significant difference in response to gefitinib plus chemotherapy according to EGFR genotype. CONCLUSION: EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib. The combination of gefitinib with chemotherapy does not improve survival in patients with these molecular markers. 相似文献
996.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. 总被引:2,自引:0,他引:2
Emiliano Honrado Ana Osorio José Palacios Roger L Milne Lydia Sánchez Orland Díez Alicia Cazorla Kirsi Syrjakoski David Huntsman P?ivi Heikkil? Enrique Lerma Anne Kallioniemi Carmen Rivas William D Foulkes Heli Nevanlinna Javier Benítez 《Journal of clinical oncology》2005,23(30):7503-7511
PURPOSE: Morphologic and immunohistochemical studies of familial breast cancers have identified specific characteristics associated with BRCA1 mutation-associated tumors when compared with BRCA2 and non-BRCA1/2 tumors, but have not identified differences between BRCA2 and non-BRCA1/2 tumors. Because BRCA1 and BRCA2 genes participate in the DNA repair pathway, we have performed an immunohistochemical study with markers related to this pathway to establish the profile of the three groups. MATERIALS AND METHODS: We have studied two tissue microarrays that include 103 familial and 104 sporadic breast tumors, with a panel of DNA repair markers including ATM, CHEK2, RAD51, RAD50, XRCC3, and proliferating cell nuclear antigen. RESULTS: We found more frequent expression of CHEK2 in BRCA1 and BRCA2 tumors than in non-BRCA1/2 and sporadic tumors. We found absence of nuclear expression and presence of cytoplasmic expression of RAD51 in BRCA2 tumors that differentiate them from other familial tumors. We validated these results with a new series of patient cases. The final study with 253 familial patient cases (74 BRCA1, 71 BRCA2, 108 non-BRCA1/2), and 288 sporadic patient cases, has allowed us to confirm our preliminary results. Because BRCA2 tumors present a specific immunohistochemical profile for RAD51 and CHEK2 markers that is different from non-BRCA1/2 tumors, we have built a multivariate model with these markers that distinguish both tumors with an estimated probability of at least 76%. CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors. 相似文献
997.
Susana B Bravo María E R García-Rendueles Rafael Seoane Vanesa Dosil José Cameselle-Teijeiro Luis López-Lázaro Juan Zalvide Francisco Barreiro Celia M Pombo Clara V Alvarez 《Clinical cancer research》2005,11(21):7664-7673
Undifferentiated (anaplastic) thyroid carcinoma is a highly aggressive human cancer with very poor prognosis. Although there have been a few studies of candidate treatments, the fact that it is an infrequent tumor makes it very difficult to design clinical trials. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations in numerous molecular genetic and expression studies. Plitidepsin (Aplidin, PharmaMar, Madrid, Spain) is a novel anticancer compound obtained from a sea tunicate. This compound has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. In initial experiments using primary cultured cells from a differentiated (papillary) carcinoma, we found that 100 nmol/L plitidepsin induced apoptosis, whereas lower doses were cytostatic. Because our aim was to study the effects of plitidepsin at clinically relevant concentrations, subsequent experiments were done with a dosage regimen reflecting plasma concentrations observed in previously reported clinical trials: 100 nmol/L for 4 hours, followed by 10 nmol/L for 20 hours (4(100)/20(10) plitidepsin). This plitidepsin dosage regimen blocked the proliferation of a primary undifferentiated/anaplastic thyroid carcinoma culture obtained in our laboratory and of a commercial cell line (8305C) obtained from an undifferentiated thyroid carcinoma; however, it did not induce apoptosis. The proportion of cells in the G(1) phase of the cell cycle was greatly increased and the proportion in the S/G(2)-M phases greatly reduced, suggesting that plitidepsin blocks G(1)-to-S transition. Levels of the cyclin D1/cyclin-dependent kinase 4/p21 complex proteins were decreased and, in line with this, the levels of unphosphorylated Rb1 increased. The decrease in cell cycle proteins correlated with hypoacetylation of histone H3. Finally, we did experiments to assess how rapidly tumor cells return to their initial pretreatment proliferative behavior after 4(100)/20(10) plitidepsin treatment. Cells from undifferentiated tumors needed more than 3 days to recover logarithmic growth, and after 7 days, cell number was still significantly lower than in control cultures. 4(100)/20(10) plitidepsin inhibited the growth in soft agar. Together, our data show that plitidepsin is able to block in vitro cell cycle progression at concentrations similar to serum concentrations observed in vivo, and that this effect is persistent for several days after plitidepsin removal. Whether plitidepsin will prove to be clinically useful in the treatment of undifferentiated thyroid cancers remains to be established. However, our results raise the possibility that plitidepsin might be effective alone or in combination with radiotherapy and/or other drug treatments. 相似文献
998.
Dolores Caballero Jose A García-Marco Rodrigo Martino Victoria Mateos José M Ribera José Sarrá Angel León Guillermo Sanz Javier de la Serna Rafael Cabrera Marcos González Jorge Sierra Jesús San Miguel 《Clinical cancer research》2005,11(21):7757-7763
PURPOSE: To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics. EXPERIMENTAL DESIGN: Eighty-three percent of patients had active disease at the moment of transplant. That is, 14 of the 23 patients analyzed (60%) had unmutated immunoglobulin variable heavy-chain gene (IgV(H)) status; 8 of 25 patients (32%) had 11q-, with four of them also displaying unmutated IgV(H); and six (24%) had 17p- (five were also unmutated). RESULTS: After a median follow-up of 47.3 months, all 22 patients alive are disease free; overall survival and event-free survival (EFS) at 6 years were 70% and 72%, respectively. According to molecular/cytogenetic characteristics, overall survival and EFS for unmutated CLL and/or with 11q- aberration (n = 13) were 90% and 92%, respectively, not significantly different to those with normal in situ hybridization, 13q- and +12, or mutated CLL (n = 7). All six patients with 17p deletion were transplanted with active disease, including three with refractory disease; all except one reached complete remission after the transplant and two are alive and disease free. Nonrelapse mortality (NRM) was 20%; more than two lines before transplant is an independent prognostic factor for NRM (P = 0,02), EFS (P = 0.02), and overall survival (P = 0.01). Patients older than 55 years have a higher risk of NRM (hazard ratio, 12.8; 95% confidence interval, 1.5-111). Minimal residual disease was monitored by multiparametric flow cytometry in 21 patients. Clearance of CD79/CD5/CD19/CD23 cells in bone marrow was achieved in 68% and 94% of the patients at days 100 and 360, respectively. CONCLUSION: According to these results, RIC allogeneic transplant could overcome the adverse prognosis of patients with unmutated CLL as well as those with 11q- or 17p-. 相似文献
999.
Xavier Leleu Ga?lle Le Friec Thierry Facon Laurence Amiot Renée Fauchet Bernadette Hennache Valérie Coiteux Ibrahim Yakoub-Agha Sylvain Dubucquoi Hervé Avet-Loiseau Claire Mathiot Régis Bataille Jean-Yves Mary 《Clinical cancer research》2005,11(20):7297-7303
Serum beta2-microglobulin, the light chain of the HLA class I molecular complex, remains one of the best survival prognostic factors in multiple myeloma, but other HLA class I molecules might be of interest in monoclonal gammopathies. In this study, we evaluate total soluble HLA class I (HLA-Is) and soluble HLA-G (HLA-Gs) in 103 patients with newly diagnosed multiple myeloma, 30 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 healthy subjects, studying their prognostic value in multiple myeloma. In multiple myeloma patients, HLA-Is and HLA-Gs median values were 0.8 microg/mL and 28 ng/mL, respectively. Median HLA-Is concentration was higher in stage II and III multiple myeloma patients than in stage I multiple myeloma, MGUS, and control patients. Median HLA-Gs was significantly lower in healthy controls than in MGUS and multiple myeloma patients. A high level of HLA-Is (> or =2.1 microg/mL) was predictive of short survival (P = 0.017). For each given level of beta2-microglobulin, the relative risk of death was higher for patients with HLA-Is > or = 2.1 microg/mL than in patients with a lower level (P = 0.047). HLA-Gs, a marker of monoclonal gammopathy, was of no prognostic value, but the addition of HLA-Is to beta2-microglobulin produced an efficient prognostic score (P < 0.0001). HLA-Is is a new marker of multiple myeloma tumor load and provides additional survival prognostic information to beta2-microglobulin. 相似文献
1000.
Anti-inflammatory effects of fructose-1,6-bisphosphate on carrageenan-induced pleurisy in rat. 总被引:3,自引:0,他引:3
José Carlos Farias Alves Filho Roberto Christ Vianna Santos Telmo Abelin Castaman Jarbas Rodrigues de Oliveira 《Pharmacological research》2004,49(3):245-248
In the present study, we evaluated the effect of fructose-1,6-bisphosphate (FBP), a high energy intermediate metabolite of glycolysis, in an acute model of lung injury. Injection of carrageenan into the pleural cavity of rats elicited an acute inflammation response characterized by a fluid accumulation in the pleural cavity which contained a large number of polymorphonuclear neutrophils. FBP (500mg/kg) attenuated the inflammation parameters: exudate volume, total leukocytes and the number of polymorphonuclear leukocytes, but the protein concentration in the exudate was not significantly affected by treatment with FBP. The precise site and mechanism of the anti-inflammatory effect was not addressed, considering the diverse pharmacological actions of FBP. This drug has anti-inflammatory actions suggesting that it may represent a novel strategy for the modulation of inflammatory response. 相似文献